View in EDS HTML Full Text PDF Full Text

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.

Saved in:
Bibliographic Details
Title: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Authors: Marcinek A; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Brauchle B; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Rohrbacher L; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Hänel G; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Philipp N; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Märkl F; Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany., Strzalkowski T; Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany., Lacher SM; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Udiljak D; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Spiekermann K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Experimental Leukemia and Lymphoma Research (ELLF), Department of Medicine III, University Hospital, LMU Munich, Munich, Germany., Theurich S; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Cancer-and Immunometabolism Research Group, LMU Gene Center, Munich, Germany., Kobold S; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany., Kischel R; AMGEN Research Munich GmbH, Munich, Germany.; AMGEN Inc., Thousand Oaks, CA, USA., James JR; Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK., Bücklein VL; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany., Subklewe M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. Marion.Subklewe@med.uni-muenchen.de.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Jul; Vol. 72 (7), pp. 2499-2512. Date of Electronic Publication: 2023 Apr 11.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37041225
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: CD33 BiTE<superscript>®</superscript> molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Marcinek+A%22">Marcinek A</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Brauchle+B%22">Brauchle B</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Rohrbacher+L%22">Rohrbacher L</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Hänel+G%22">Hänel G</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Philipp+N%22">Philipp N</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Märkl+F%22">Märkl F</searchLink>; Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Strzalkowski+T%22">Strzalkowski T</searchLink>; Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Lacher+SM%22">Lacher SM</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Udiljak+D%22">Udiljak D</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Spiekermann+K%22">Spiekermann K</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Experimental Leukemia and Lymphoma Research (ELLF), Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Theurich+S%22">Theurich S</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Cancer-and Immunometabolism Research Group, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kobold+S%22">Kobold S</searchLink>; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Division of Clinical Pharmacology, Department of Medicine IV; Member of the German Center for Lung Research (DZL), University Hospital, LMU, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Kischel+R%22">Kischel R</searchLink>; AMGEN Research Munich GmbH, Munich, Germany.; AMGEN Inc., Thousand Oaks, CA, USA.<br /><searchLink fieldCode="AU" term="%22James+JR%22">James JR</searchLink>; Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.<br /><searchLink fieldCode="AU" term="%22Bücklein+VL%22">Bücklein VL</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Subklewe+M%22">Subklewe M</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Marion.Subklewe@med.uni-muenchen.de.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. Marion.Subklewe@med.uni-muenchen.de.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2023 Jul; Vol. 72 (7), pp. 2499-2512. <i>Date of Electronic Publication: </i>2023 Apr 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37041225
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-023-03439-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2499
    Titles:
      – TitleFull: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Marcinek A
      – PersonEntity:
          Name:
            NameFull: Brauchle B
      – PersonEntity:
          Name:
            NameFull: Rohrbacher L
      – PersonEntity:
          Name:
            NameFull: Hänel G
      – PersonEntity:
          Name:
            NameFull: Philipp N
      – PersonEntity:
          Name:
            NameFull: Märkl F
      – PersonEntity:
          Name:
            NameFull: Strzalkowski T
      – PersonEntity:
          Name:
            NameFull: Lacher SM
      – PersonEntity:
          Name:
            NameFull: Udiljak D
      – PersonEntity:
          Name:
            NameFull: Spiekermann K
      – PersonEntity:
          Name:
            NameFull: Theurich S
      – PersonEntity:
          Name:
            NameFull: Kobold S
      – PersonEntity:
          Name:
            NameFull: Kischel R
      – PersonEntity:
          Name:
            NameFull: James JR
      – PersonEntity:
          Name:
            NameFull: Bücklein VL
      – PersonEntity:
          Name:
            NameFull: Subklewe M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2023 Jul
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 72
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1